Minolira is a drug owned by Epi Health Llc. It is protected by 1 US drug patent filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 07, 2036. Details of Minolira's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11103517 | Pharmaceutical compositions for minocycline |
Apr, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Minolira's patents.
Latest Legal Activities on Minolira's Patents
Given below is the list of recent legal activities going on the following patents of Minolira.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation | 31 Aug, 2021 | US11103517 |
| Recordation of Patent Grant Mailed | 31 Aug, 2021 | US11103517 |
| Email Notification | 12 Aug, 2021 | US11103517 |
| Issue Notification Mailed | 11 Aug, 2021 | US11103517 |
| Dispatch to FDC | 29 Jul, 2021 | US11103517 |
| Application Is Considered Ready for Issue | 29 Jul, 2021 | US11103517 |
| Issue Fee Payment Verified | 26 Jul, 2021 | US11103517 |
| Issue Fee Payment Received | 26 Jul, 2021 | US11103517 |
| Mailing Corrected Notice of Allowability | 26 Jul, 2021 | US11103517 |
| Email Notification | 26 Jul, 2021 | US11103517 |
US patents provide insights into the exclusivity only within the United States, but Minolira is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Minolira's family patents as well as insights into ongoing legal events on those patents.
Minolira's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Minolira's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 07, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Minolira Generics:
Minocycline Hydrochloride is the generic name for the brand Minolira. 26 different companies have already filed for the generic of Minolira, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Minolira's generic
About Minolira
Minolira is a drug owned by Epi Health Llc. Minolira uses Minocycline Hydrochloride as an active ingredient. Minolira was launched by Epi Hlth in 2017.
Market Authorisation Date:
Minolira was approved by FDA for market use on 08 May, 2017.
Active Ingredient:
Minolira uses Minocycline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Minocycline Hydrochloride ingredient
Dosage:
Minolira is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 105MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| EQ 135MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |